5 Key Takeaways
-
1
Legend Biotech's in vivo CAR-T therapy showed promising phase 1 results, with five of six patients achieving complete response to LB2501.
-
2
Kelonia Therapeutics' in vivo BCMA CAR T therapy eliminated disease signs in all 18 patients with multiple myeloma one month post-treatment.
-
3
Induced pluripotent stem cell-derived engineered heart muscle improved heart function in patients with heart failure in a phase 1-2 study.
-
4
Dual CAR-T therapy enabled two end-stage kidney disease patients to receive kidney transplants by reducing harmful immune antibodies.
-
5
Researchers developed a method to enhance CAR T cell migration to lymph nodes, improving efficacy against B-cell malignancies in mice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
